The cost of treatment in new case and multidrug resistant case in pulmonary tuberculosis

Basit Öğe Kaydı
dc.authorscopusid6603196879
dc.authorscopusid6507965905
dc.authorscopusid8712477800
dc.authorscopusid6603204670
dc.contributor.authorKizkin O.
dc.contributor.authorHacievliyagil S.S.
dc.contributor.authorTürker G.
dc.contributor.authorGünen H.
dc.date.accessioned2024-08-04T19:59:30Z
dc.date.available2024-08-04T19:59:30Z
dc.date.issued2003
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe treatment of multidrug-resistant pulmonary tuberculosis (MDR-Tbc) is quite difficult, and the disease has high morbidity and mortality rates. This study was designed to compare the costs of treatment in new tuberculosis (new-Tbc) cases and MDR-Tbc cases. Data base of the study was composed of the data from therapy principles of new-Tbc cases and MDR-Tbc, and official directives and price lists of Turkish Pharmacology Society in 2001 fiscal year regulating treatment costs. For new-Tbc cases, the treatment cost included expanses for 20 days of hospitalisation, one month work loss and six months drug supply and laboratory costs; for MDR-Tbc cases, it was comprised by expenses for seven months hospitalisation in average, 12 months work loss, 24 months drug supply and laboratory costs, and probable surgical interventions and post-operative intensive care. The service of hospital stuff and medical equipment provided was disregarded. The cost analyses was calculated as charge price of American dollars ($) dated 14.09.2001. It was found that the cost of therapy for new-Tbc cases and MDR-Tbc cases were 1134.89 $ and 17529.15 $, respectively. In MDR-Tbc cases, the costs of hospitalisation, work loss, drug therapy and laboratory procedures were 10.5, 12, 98.7 and 5.3 times higher respectively, when compared with those of new-Tbc. The cost of thoracotomy for one patient including the cost for 10 days period of post-operative care in intensive care unit was 391.93 $. The treatment of MDR-Tbc has a high cost, and 16 new-Tbc cases can be treated with the same cost in our country. In conclusion, we think that successful treatment strategies for both new-Tbc cases and MDR-Tbc cases will lower the cost of tuberculosis treatment.en_US
dc.identifier.endpage415en_US
dc.identifier.issn0494-1373
dc.identifier.issue4en_US
dc.identifier.pmid15143390en_US
dc.identifier.scopus2-s2.0-21644462509en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage410en_US
dc.identifier.urihttps://hdl.handle.net/11616/90667
dc.identifier.volume51en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isotren_US
dc.relation.ispartofTüberküloz ve toraksen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecttuberculostatic agenten_US
dc.subjectarticleen_US
dc.subjectcomparative studyen_US
dc.subjectdrug costen_US
dc.subjecteconomicsen_US
dc.subjecthospital costen_US
dc.subjecthospitalizationen_US
dc.subjecthumanen_US
dc.subjectlung tuberculosisen_US
dc.subjectstatisticsen_US
dc.subjecttuberculosisen_US
dc.subjectTurkey (republic)en_US
dc.subjectAntitubercular Agentsen_US
dc.subjectDrug Costsen_US
dc.subjectHospital Costsen_US
dc.subjectHospitalizationen_US
dc.subjectHumansen_US
dc.subjectTuberculosis, Multidrug-Resistanten_US
dc.subjectTuberculosis, Pulmonaryen_US
dc.subjectTurkeyen_US
dc.titleThe cost of treatment in new case and multidrug resistant case in pulmonary tuberculosisen_US
dc.title.alternativeCok ilaca dirençli akciger tüberkülozu ile yeni olgu akciger tüberkülozunun tedavi maliyeti.en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu